EMA advises on how to prevent medication errors with new forms and indications
This article was originally published in SRA
In yet another move prompted by the new EU pharmacovigilance legislation, companies proposing to market products similar to ones already on the market are being asked to take extra steps to prevent potential medication errors, particularly involving substances that have a narrow therapeutic index1.
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.